Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779872 | 0.88 | JAK1 (0.43) | JAK1CNR1PDK4SCN9ADGAT2 | |
| SCHEMBL28458030 | 0.87 | RXRA (0.39) | JAK1NAMPT | |
| SCHEMBL22723600 | 0.87 | JAK1 (0.45) | JAK1CNR1PDK4SCN9ADGAT2 | |
| SCHEMBL20437474 | 0.83 | JAK1 (0.45) | JAK1PDK4SCN9AHTR6GABRP | |
| SCHEMBL21796837 | 0.83 | TNF (0.46) | JAK1PDK4SCN9AHTR6CDK9 | |
| SCHEMBL21894611 | 0.82 | CDK9 (0.35) | JAK1CDK9NAMPTKRAS | |
| SCHEMBL17731773 | 0.81 | MEN1 (0.43) | SCN9AKRASNR3C1 | |
| SCHEMBL30610187 | 0.81 | MEN1 (0.43) | SCN9AKRASNR3C1 | |
| SCHEMBL24638317 | 0.81 | RXRA (0.51) | JAK1SCN9ATBK1CDK7CDK13 | |
| SCHEMBL21796569 | 0.81 | NAMPT (0.45) | JAK1PDK4SCN9ATBK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215156-B1 | INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE | IOMET PHARMA LTD (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | JAK1 1650/4885CNR1 241/4885PDK4 1122/4885 |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | JAK1 1650/4885CNR1 241/4885PDK4 1122/4885 |
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | JAK1 1650/4885CNR1 241/4885PDK4 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.